Lantheus Holdings, Inc. (NASDAQ:LNTH) Insider Etienne Montagut Sells 7,435 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTH) insider Etienne Montagut sold 7,435 shares of the business’s stock in a transaction dated Friday, June 4th. The shares were sold at an average price of $24.60, for a total transaction of $182,901.00. Following the completion of the transaction, the insider now owns 87,719 shares in the company, valued at approximately $2,157,887.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:LNTH opened at $24.40 on Friday. Lantheus Holdings, Inc. has a one year low of $10.52 and a one year high of $25.79. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.61 and a quick ratio of 2.14. The business’s 50-day simple moving average is $22.20. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -135.55, a P/E/G ratio of 2.12 and a beta of 1.24.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, May 4th. The medical equipment provider reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. Lantheus had a negative net margin of 2.29% and a positive return on equity of 2.87%. The business had revenue of $92.51 million for the quarter, compared to analyst estimates of $87.24 million. During the same quarter in the previous year, the firm posted $0.36 earnings per share. Lantheus’s quarterly revenue was up 2.0% on a year-over-year basis. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 0.35 earnings per share for the current year.

Several equities analysts recently issued reports on LNTH shares. SVB Leerink boosted their price target on shares of Lantheus from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, April 28th. Zacks Investment Research cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, May 12th. Finally, Credit Suisse Group boosted their price target on shares of Lantheus from $17.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, May 5th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Lantheus presently has an average rating of “Buy” and a consensus target price of $26.25.

Large investors have recently bought and sold shares of the stock. Credit Suisse AG boosted its stake in Lantheus by 64.2% during the fourth quarter. Credit Suisse AG now owns 76,228 shares of the medical equipment provider’s stock worth $1,029,000 after acquiring an additional 29,794 shares in the last quarter. BlackRock Inc. boosted its stake in Lantheus by 4.4% during the fourth quarter. BlackRock Inc. now owns 10,291,302 shares of the medical equipment provider’s stock worth $138,829,000 after acquiring an additional 435,251 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Lantheus by 3.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 40,027 shares of the medical equipment provider’s stock worth $540,000 after acquiring an additional 1,468 shares in the last quarter. LPL Financial LLC bought a new stake in Lantheus during the fourth quarter worth about $326,000. Finally, Captrust Financial Advisors lifted its stake in shares of Lantheus by 4.3% in the fourth quarter. Captrust Financial Advisors now owns 52,482 shares of the medical equipment provider’s stock worth $708,000 after buying an additional 2,170 shares in the last quarter. 90.93% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.

Further Reading: What is a death cross?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.